Looking at options history for Vertex Pharmaceuticals (NASDAQ: VRTX) we detected 10 trades. If we consider the specifics of ...
ClearBridge Investments, an investment management company, released its “ClearBridge Large Cap Growth Strategy” third-quarter ...
Fintel reports that on October 10, 2025, Morgan Stanley maintained coverage of Vertex Pharmaceuticals (NasdaqGS:VRTX) with a Equal-Weight recommendation. Analyst Price Forecast Suggests 18.17% Upside ...
If you're holding shares of Vertex Pharmaceuticals or thinking about adding some to your portfolio, you're not alone in ...
Zacks Investment Research on MSN
Investors Heavily Search Vertex Pharmaceuticals Incorporated (VRTX): Here is What You Need to Know
Vertex Pharmaceuticals (VRTX) has recently been on Zacks.com's list of the most searched stocks. Therefore, you might want to ...
Vertex Pharmaceuticals’ CRISPR-based therapy made history as the first drug of its type, transforming care options for sickle ...
Detailed price information for Vertex Pharmaceutic (VRTX-Q) from The Globe and Mail including charting and trades.
As the industry loses one of its key female leaders in GSK CEO Emma Walmsley, BioSpace profiles the women leading the ...
Detailed price information for Vertex Pharmaceutic (VRTX-Q) from The Globe and Mail including charting and trades.
Preclinical data presented at the European Society of Gene and Cell Therapy (ESGCT) highlight a potential best-in-class profile--The AATD ...
The company had to abandon the development of a medicine for type 1 diabetes (T1D), while another therapy in development for acute pain failed a phase 2 study. The biotech company also encountered ...
Ian Smith, the former chief financial officer of Vertex Pharmaceuticals, has taken over as CEO of Stoke Therapeutics.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback